FSD BIO LABS · Product artwork
Studied for appetite regulation, satiety and weight management.
20 vials available
Full prepaid by UPI includes free delivery. COD requires 5% advance and a 1.5% delivery fee. Payment details
See delivery information and return conditions before ordering. Your final total is shown at checkout.
COA not yet available for this strength
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Cagrilintide is a long-acting analogue of amylin, a hormone involved in the regulation of food intake. Clinical research has investigated its role in weight management through amylin-related signalling.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
A randomised trial compared a clinical cagrilintide formulation with placebo and an active comparator in adults with overweight or obesity. It does not validate this catalogue vial.
Read sourceThe study compared a cagrilintide–semaglutide combination, each component alone and placebo. The main comparison concerned the combination; its results should not be described as cagrilintide-alone effects.
Read sourceCAGRILINTIDE is currently listed in 5 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
The references discuss the material and experimental conditions in those studies. They do not verify the identity, purity, quantity or suitability of this catalogue vial. Review the study limitations and the available batch documentation separately.
Studied for weight management, appetite regulation and metabolic signalling.